Page 9 - Nasdaq Allo News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Allogene Therapeutics (NASDAQ:ALLO – Get Rating) and SAB Biotherapeutics (NASDAQ:SABS – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, valuation, analyst recommendations, dividends and institutional ownership. Risk & Volatility Allogene Therapeutics has a beta of […]

Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Rating) have received an average rating of “Buy” from the fifteen analysts that are currently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and eleven have assigned a buy recommendation to the company. The average 1-year price objective […]

Allogene Therapeutics (NASDAQ:ALLO – Get Rating)‘s stock had its “buy” rating reiterated by research analysts at JMP Securities in a research note issued to investors on Monday, TipRanks reports. They currently have a $23.00 target price on the stock. JMP Securities’ price target would suggest a potential upside of 171.23% from the stock’s previous close. […]

Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Rating) have been assigned an average recommendation of “Buy” from the fifteen ratings firms that are covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The average twelve-month price […]

SOUTH SAN FRANCISCO, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company...